TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with care question
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experience Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of monogenic diabetes among patients diagnosed as type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients carrying mutations in previously unstudied genes that meet statistical criteria of pathogenicity for monogenic diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to net whole body protein metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular Symptoms and Signs Total Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With IGA Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life improvement (measured by KCCQ score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Self-efficacy at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with Care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Specific antibody response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of symptoms from benign prostatic hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Status at the End of CDI Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of family history of VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Medical misuse of opioids or sedatives
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Accumulation of Disability (SAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Immunogenicity of Swine A/H1N1 influenza vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery rate of cutaneous warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of ACOS among patients with persistent airflow limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Audiologic Rehabilitation Self-efficacy for Hearing Aids score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Volumetric Bone Mineral Density (vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Areal Bone Mineral Density (aBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAR-4 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in thrombin and fibrin turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Kidney histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Numeric Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Anterior Knee Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Tinnitus Functional Index Change Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC tau,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute bladder and bowel toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cardiac assessment findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in clinical laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical exam finding, including vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recruited participants retained for the 12-week intervention period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in average weekly pain on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Rating of Pain for the Study Period (12 Weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Difference Between WOMAC Pain Subscale Score From Baseline to the End of the Study (Week 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Difference Between WOMAC Physical Function Subscale Score From Baseline to the End of the Study (Week 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to brachial plexus block performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Palpebral Fissure Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mobility performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of physical capacities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinician Detection of major depression, generalized anxiety, PTSD, or alcohol dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Morris Disability Questionnaire (RDQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-lead safety ECG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ≥1 SRE
Endpoint domain: Adverse events/effects
Primary endpoint: Volumetrical and densitometric data of brain tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of middle deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of visual function index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of participants with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Functional capacity with a validated questionnaire (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in kinesiophobia level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of identification of eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible patients consenting to participate and randomized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the rate of adherence to the trial interventions from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of PR, QRS, QTc, QT and Tp-e intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of iCEB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the duration of crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of RFPP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of RFPP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fidelity of RFPP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Whole-body insulin sensitivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Perceived Stress Levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Suicide Attempt Self Injury Interview (SASII)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of pathological complete response [ypCR]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events related to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Repair capacity of PBS® CIMMO and Zinc Oxide cements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Differential luminance sensitivity (DLS) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in vaccination rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with drug or procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of XL184
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of XL184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Complete Planned Oncologic Therapy Without Hematological Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Tolerated Dose of Ribociclib and Everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Tumor and Plasma Concentrations of Ribociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum Apixaban Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients who complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient satisfaction with the timing, content, and delivery of the video-based intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relapse of bullous pemphigoid
Endpoint domain: Adverse events/effects
Primary endpoint: Intra-Operative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Flow-mediated Vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Carotid Intima Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relapse of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects with viral loads <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Normal Serum Calcium Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of modified Rankin Score (mRS) higher than 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoints of Deep vein Thrombosis, non-fatal PE and death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: FEDSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleurodesis/Pleural Catheter Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: The Patient Health Questionnaire 8 (PHQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Syringe-sharing
Endpoint domain: Adverse events/effects
Primary endpoint: Syringe-sharing partners
Endpoint domain: Adverse events/effects
Primary endpoint: Secondary injection equipment-sharing
Endpoint domain: Adverse events/effects
Primary endpoint: Secondary injection equipment-sharing partners
Endpoint domain: Adverse events/effects
Primary endpoint: Backloading
Endpoint domain: Adverse events/effects
Primary endpoint: Backloading partners
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy on tracheostomy care scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients on oral anticoagulation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in hsCRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Il-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in procalcytonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete resolution of heartburn and regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GL Severity at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of extubation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in SLEDAI-2K Responder Index-50 (SRI-50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD of Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymptomatic ICH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Duration of 20% Dextrose Infusion Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent organ dysfunction plus death (POD + death) 7 days after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Cardiac Frequency Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Estimated birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall Mental Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Combined Verbal Ability scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Combined Reasoning Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Patients Free of All ITP Therapy with Platelet Count ≥ 50,000/μl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence or absence of post-operative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Major Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression of Salivary Biomarkers of Bone Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker FACES Pain Rating Scale (WB-FACES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Fear Scale (CFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in 6 minute walk distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Head, neck, or jaw movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local anesthetic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of CD8+ T Cells Expressing Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathologic tumor regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of [89Zr]Df-IAB2M PET
Endpoint domain: Adverse events/effects
Primary endpoint: Pure Tone Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number/Percent of Adult Subjects Experiencing Myalgia Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number/Percent of Adult Subjects Experiencing Headache Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve From Time Zero Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Response Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: New-onset postoperative atrial fibrillation rate (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All cause 30-day hospital readmission rate (%)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospital length of stay, days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in temporal variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spatial variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor VIII (FVIII) Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Asthma Control at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Control at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Plasma Cholesterol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Triglyceride Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma High Density Lipoproteins Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Low Density Lipoproteins Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of F3-4 fibrosis or cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: intra-operative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post operative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Study Baseline Over Time in Supine Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Postdose Supine Blood Pressure Less Than 130/80 mmHg Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Number of Conventional Cigarettes Smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change from Baseline of inflammatory lesion counts of rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Colonization of the Oral Cavity by Respiratory Pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes